Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 26 Feb 2024 |
| Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab | 23 Feb 2024 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 23 Feb 2024 |
| Transactions in connection with share buy-back program | 19 Feb 2024 |
| Notice to Convene the Annual General Meeting of Genmab A/S | 15 Feb 2024 |
| Genmab Publishes 2023 Annual Report | 14 Feb 2024 |